Stockscreener 앱 받기
204.56
1.44%
2.90
시간 외 거래:
204.56
전일 마감가:
$201.66
열려 있는:
$203.17
하루 거래량:
140.30K
Relative Volume:
0.65
시가총액:
$4.08B
수익:
$268.09M
순이익/손실:
$124.45M
주가수익비율:
35.06
EPS:
5.8347
순현금흐름:
$38.05M
1주 성능:
-2.37%
1개월 성능:
+6.88%
6개월 성능:
+22.67%
1년 성능:
+86.49%
1일 변동 폭
$201.28
$208.89
1주일 범위
$195.45
$214.45
52주 변동 폭
$93.58
$227.92
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
204.56 | 4.02B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | BofA Securities | Buy |
| 2025-12-09 | 개시 | Citigroup | Buy |
| 2025-04-10 | 개시 | Stifel | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
Insider Sell: Stephen Sabba Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 1,000 Shares of Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $207,872 in stock - Investing.com
Ligand Pharmaceuticals (LGND) director sells 1,000 shares, keeps stake - Stock Titan
Ligand Pharmaceuticals (LGND) Receives Updated Price Target from Citigroup | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $276.00 at Citigroup - MarketBeat
Ligand Pharmaceuticals (LGND) Receives Target Price Boost from C - GuruFocus
Congress Asset Management Co. Sells 187,248 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Stephen Sabba (NASDAQ: LGND) sells 2,034 shares for $409,851 - Stock Titan
AI Stocks: How does Ligand Pharmaceuticals Incorporated score in quality rankingsWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Tudor Investment Corp ET AL Takes $2.79 Billion Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model - Seeking Alpha
Penn Capital Management Company LLC Trims Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Acuitas Investments LLC Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Granahan Investment Management LLC Purchases Shares of 24,962 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Clark Capital Management Group Inc. Acquires 11,858 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals is a low-risk way to bet on biopharma growth: Analyst - MSN
Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight - simplywall.st
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Octavio Espinoza Sells 3,057 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $687k in shares By Investing.com - Investing.com Canada
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView
Ligand (NASDAQ: LGND) CFO trades shares under 10b5-1 plan - Stock Titan
How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story - simplywall.st
Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating - Yahoo Finance
Russell Investments Group Ltd. Sells 9,403 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Down 9.1%Time to Sell? - MarketBeat
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
This Ligand Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Octavio Espinoza sells shares under 10b5-1 plan (LGND) - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
Victory Capital Management Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals CFO sells $2.76 million in shares By Investing.com - Investing.com South Africa
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):